Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 108.46 Million USD | -6.01% |
| 2021 | 115.39 Million USD | 25.59% |
| 2020 | 91.88 Million USD | 6.4% |
| 2019 | 86.35 Million USD | 48.63% |
| 2018 | 58.1 Million USD | 111.05% |
| 2017 | 27.53 Million USD | 111.37% |
| 2016 | 13.02 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 24.9 Million USD | 18.08% |
| 2023 Q3 | 10.39 Million USD | -42.14% |
| 2023 Q2 | 17.95 Million USD | -27.88% |
| 2022 Q2 | 29.58 Million USD | 2.95% |
| 2022 Q3 | 29.05 Million USD | -1.8% |
| 2022 FY | 108.46 Million USD | -6.01% |
| 2022 Q1 | 28.73 Million USD | 4.28% |
| 2022 Q4 | 21.08 Million USD | -27.42% |
| 2021 Q4 | 27.55 Million USD | -15.75% |
| 2021 Q1 | 27.47 Million USD | -2.58% |
| 2021 Q2 | 27.65 Million USD | 0.67% |
| 2021 FY | 115.39 Million USD | 25.59% |
| 2021 Q3 | 32.71 Million USD | 18.27% |
| 2020 Q3 | 20.18 Million USD | -0.31% |
| 2020 Q2 | 20.24 Million USD | -12.97% |
| 2020 Q4 | 28.19 Million USD | 39.72% |
| 2020 FY | 91.88 Million USD | 6.4% |
| 2020 Q1 | 23.26 Million USD | 2.61% |
| 2019 Q4 | 22.67 Million USD | 5.46% |
| 2019 Q2 | 21.38 Million USD | 2.8% |
| 2019 Q1 | 20.8 Million USD | 30.08% |
| 2019 FY | 86.35 Million USD | 48.63% |
| 2019 Q3 | 21.49 Million USD | 0.51% |
| 2018 Q2 | 15.22 Million USD | 46.07% |
| 2018 FY | 58.1 Million USD | 111.05% |
| 2018 Q4 | 15.99 Million USD | -2.82% |
| 2018 Q3 | 16.45 Million USD | 8.07% |
| 2018 Q1 | 10.42 Million USD | 29.23% |
| 2017 Q1 | 5.2 Million USD | 0.0% |
| 2017 Q2 | 6.21 Million USD | 19.39% |
| 2017 Q3 | 8.03 Million USD | 29.27% |
| 2017 Q4 | 8.06 Million USD | 0.36% |
| 2017 FY | 27.53 Million USD | 111.37% |
| 2016 FY | 13.02 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -16303.622% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -1070.328% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -261.638% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -61.535% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -584.63% |
| Better Therapeutics, Inc. | 38.26 Million USD | -183.482% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -166.573% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -775.239% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -220.488% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -215.134% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -10825.163% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -232.83% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -131.02% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -8829.536% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -443.981% |
| Molecular Templates, Inc. | 63.09 Million USD | -71.92% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -678.561% |
| NexImmune, Inc. | 28.16 Million USD | -285.075% |
| Orgenesis Inc. | 45.75 Million USD | -137.048% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -322.919% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -147641.637% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -571.813% |
| Scopus BioPharma Inc. | 11.71 Million USD | -825.883% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 73.123% |
| Statera Biopharma, Inc. | 28.82 Million USD | -276.233% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -473.015% |
| Trevena, Inc. | 38.41 Million USD | -182.368% |
| Vaxxinity, Inc. | 56.05 Million USD | -93.513% |
| Vaccinex, Inc. | 23.45 Million USD | -362.443% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -10259.912% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -113.966% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -1391.019% |